Consumption of milk fat and reduced asthma risk in pre-school children

We read the paper by Wijga et al1 published in the July 2003 issue of Thorax with great interest. The authors found that the consumption of specific food items such as full cream milk, butter, and brown bread can contribute to a decrease in the risk of asthma and wheezing in pre-school children. These findings agree with previous studies in adults,2 but there are a few methodological problems in the analyses used in the study which may have influenced the results obtained.

Our first area of concern is that trans-generational traditions of families with atopic diseases are not taken into consideration. For instance, families with a history of atopy tend to smoke less, which is described as a “healthy passive smoker effect”.3,4 Grandparents and parents who have asthma tend not to smoke, but their children are more likely to develop atopic manifestations than children from smoking families without asthma. It is also likely that atopic parents change their exposure to pets which may lead to a similar “healthy pet keeping effect”.5 For related reasons, families may also alter their diets resulting in a “healthy cow’s milk effect”. These potential changes within families are supported by avoidance strategies propagated by various national medical associations. Children of atopic parents therefore tend to experience different exposures. Hence, before using statistical models we need to investigate the extent to which the diet of children differs according to the atopic status of their parents. An additional table is therefore needed, comparable to table 2, with consumption frequencies in columns for paternal allergy and the prevalence of wheeze: full cream milk, milk products (containing milk fat), and butter and brown bread (table 1, first column).

To add to this argument, the authors also failed to differentiate between allergic and non-allergic (transient?) wheezing. We look forward to seeing additional informative tables.

W Karmaus, C Fussman
Michigan State University, College of Human Medicine, Department of Epidemiology, East Lansing, Michigan 48823, USA; karmaus@msu.edu

Figure 1 Causal transmission of trans-generational risks for asthma.

If you have a burning desire to respond to a paper published in Thorax, why not make use of our “rapid response” option.

Log on to our website (www.thoraxjnl.com), find the paper that interests you, and send your response via email clicking on the “eletters” option in the box at the top right hand corner.

Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eletters” on our homepage.

The editors will decide as to whether to also publish it in a future paper issue.

References

Authors’ reply

The first point made by Karmaus and Fussman is that the association we observed between consumption of products containing milk fat (full cream milk, milk products, butter) and a reduced risk of asthma in pre-school children could be the result of a “healthy cow’s milk effect.”6 This is unlikely as avoidance of cow’s milk is uncommon in the Netherlands. Dutch guidelines do not advise avoidance of cow’s milk for children with familial allergy after the age of 12 months unless the child has cow’s milk allergy.7 The popular belief is that young children need milk for healthy growth and few parents see milk as potentially harmful.99% of Dutch children aged 1–4 years use milk (products).1 In the PIAMA population, too, nearly all children used milk—either full cream or semi-skimmed. Apart from 64 children with cow’s milk allergy who were excluded from the analyses, only 27 children (<1%) had not used milk (products) in the previous month. Of these children, 16 had an allergic parent and 11 had non-allergic parents. The data requested by Karmaus and Fussman do not show an association between parental allergy and the prevalence of daily consumption of the foods that we found to be associated with reduced risk of asthma or wheeze: full cream milk, milk products (mainly flavoured and unflavoured yoghurt, either full cream or low fat), butter and brown bread (table 1, first column).

Karmaus and Fussman correctly point out the imbalance between the percentages of allergic mothers and allergic fathers in the study. This imbalance is due to the study design. Maternal allergy was used as the criterion to allocate participants to subgroups of the PIAMA study and in the natural history part of the study non-allergic mothers were oversampled.

The second point of concern raised by Karmaus and Fussman deals with our logistic regression model. They state that, by treating parental allergy as a confounder, we neglected the epidemiological rule that intervening variables should not be considered as confounders. However, in their fig 1, parental...
Table 1 Percentages and (numbers) of 2 year old children who consumed different foods on 6 or 7 days/week, crude prevalences of asthma and wheeze at age 3 in children who, at age 2, used different foods on a daily basis (“daily use”) compared with children with lower consumption frequencies (others) and adjusted odds ratios† for the relationship between daily consumption‡ of different foods at age 2 and prevalence of asthma and wheeze at age 3, stratified for parental allergy

<table>
<thead>
<tr>
<th>Foods</th>
<th>Parental allergy</th>
<th>&quot;Ever asthma&quot;</th>
<th>Recent asthma</th>
<th>Recent wheeze</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&quot;Daily use&quot;</td>
<td>&quot;Others&quot;</td>
<td>&quot;Daily use&quot;</td>
<td>&quot;Others&quot;</td>
</tr>
<tr>
<td></td>
<td>Adjusted OR (95% CI)</td>
<td></td>
<td>Adjusted OR (95% CI)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Percentages (%)</td>
<td>Crude % prevalence</td>
<td>Percentages (%)</td>
<td>Crude % prevalence</td>
</tr>
<tr>
<td></td>
<td>(n = 1816)</td>
<td>(n = 1962)</td>
<td>(n = 2001)</td>
<td>(n = 2047)</td>
</tr>
<tr>
<td></td>
<td>Milk products</td>
<td>75.1</td>
<td>4.6</td>
<td>6.7</td>
</tr>
<tr>
<td></td>
<td>Full cream milk</td>
<td>62.8</td>
<td>7.3</td>
<td>7.3</td>
</tr>
<tr>
<td></td>
<td>Butter</td>
<td>7.0</td>
<td>4.0</td>
<td>5.2</td>
</tr>
<tr>
<td></td>
<td>Milk products</td>
<td>74.1</td>
<td>8.1</td>
<td>10.4</td>
</tr>
<tr>
<td></td>
<td>Full cream milk</td>
<td>85.2</td>
<td>7.8</td>
<td>14.3</td>
</tr>
<tr>
<td></td>
<td>Butter</td>
<td>6.3</td>
<td>7.0</td>
<td>9.2</td>
</tr>
<tr>
<td></td>
<td>Only maternal allergy</td>
<td>32.9</td>
<td>5.4</td>
<td>11.1</td>
</tr>
<tr>
<td></td>
<td>Milk products</td>
<td>73.9</td>
<td>8.9</td>
<td>10.1</td>
</tr>
<tr>
<td></td>
<td>Full cream milk</td>
<td>84.8</td>
<td>8.1</td>
<td>15.6</td>
</tr>
<tr>
<td></td>
<td>Butter</td>
<td>7.1</td>
<td>0.0</td>
<td>9.9</td>
</tr>
</tbody>
</table>

†Adjusted for consumption frequencies of foods shown in the table, consumption frequency of skimmed milk, consumption frequency of margarine, sex, birth weight, presence of older siblings, maternal education, having brown bread for >8 weeks, and parental smoking at home.

‡For full cream milk and butter odds ratios are shown for daily consumption (on 6–7 days/week) compared with consumption less than once a week; for milk products and brown bread the prevalence of consumption less than once a week is less than 5% and therefore odds ratios are shown for daily consumption versus all others.

We conclude that there is no evidence in our population for a “healthy full cream cow’s milk effect”, that we adjusted correctly for parental allergy in our analyses, and that our data do not suggest that the reported associations between daily consumption of products containing milk fat and reduced risk of asthma and wheeze are only present in children of non-allergic parents.

A H Wijsa, H C Bosshuizen, H A Smit
National Institute of Public Health and the Environment, Department of Chronic Disease Epidemiology (CZE), The Netherlands

M Kerkhof, J Gerritsen
Department of Paediatric Respiratory Medicine, University Hospital Groningen, Groningen, The Netherlands

J C de Jongste, H J Neijens (deceased)
Department of Paediatrics, Erasmus University Medical Center/Sophia Children’s Hospital, Rotterdam, The Netherlands

B Brunekreef
Institute for Risk Assessment Sciences, University of Utrecht, Utrecht, The Netherlands

Correspondence to: Dr A Wijsa, National Institute of Public Health and the Environment, Department of Chronic Disease Epidemiology (CZE), P O Box 1, 3720BA Bilthoven, The Netherlands; alej.wijsa@rivm.nl

References


BIS/BTS SARS guidelines

The guidelines on severe acute respiratory syndrome (SARS) published by the British Infection Society (BIS) and the British Thoracic Society (BTS) in July 2003 recommend giving adult patients with suspected or probable SARS an N95 or equivalent mask and request that they wear this continuously.† This recommendation was apparently provided to prevent the spread of the SARS coronavirus from the patient to the surrounding environment.

An N95 respirator (mask) is a negative pressure respirator which only filters air entering the mask, not leaving it. Those wearing this respirator will experience an additional burden on the breathing system in moving air in and out of the respirator.† For this reason, occupational protection agencies such as the United States Occupational Safety and Health Administration† require those using these types of respirator to be medically qualified because of physiological and psychological stresses that may occur. Patients with SARS coronavirus will certainly not meet these requirements and use of a respirator will only add to their pulmonary stress. Since there will be no filtration of air leaving the wearer of this respirator, little protection besides that of a barrier will occur, allowing viral spread from the patient with limited impedance. It has also been suggested† that N95 respirators, even when properly used by healthcare workers, do not provide adequate protection against the SARS virus.

The recommendation should be changed to eliminate the requirement of the patient using a respirator and instead shifting this requirement to healthcare workers. This will provide the best protection against the spread of SARS coronavirus. It has recently been
suggested that a high ventilation rate in hospitalwards with SARS patients results in the proper use of personal protective equipment, including respirators, by healthcare workers together with a high ventilation rate. The guidelines should be adjusted to recommend that patients should not wear a respirator.

J Lange
Envirosafe Training and Consultants, P O Box 114022, Pittsburgh, PA 15239, USA; johnlange@worldnet.att.net

References
2 Lange JH. A revising of the appropriate respiratory protection against SARS. Can Med Assoc J 2004;174:445

Authors’ reply
We thank Mr Lange for his comments on the BTS/BIS SARS guidelines of July 2003. He and other Thorax readers will be pleased to know that the guidelines have been rewritten over the last few months and are now on the BTS website under the title “Hospital management of adults with SARS if SARS re-emerges”.

The new BTS/BIS/HPA guidelines recommend that all possible or probable SARS patients should wear a surgical face mask rather than an N95 respirator, and that healthcare workers should wear a respirator complying with the European standard EN149:2001 FFP3 or higher filtration. Healthcare workers should note that wearing a respirator is just one way of preventing the spread of SARS; other important precautions include good personal hygiene (especially hand hygiene) and gloves, aprons, gowns, visors, and goggles when appropriate. For further up to date information please visit the UK Health Protection Agency (HPA) website.

The UK Health Protection Agency continues to urge healthcare workers to remain vigilant to the possibility of SARS even though the level of risk in the UK remains very low.

S R Anderson, W S Lim
SARS Guidelines Committee of the British Thoracic Society, the British Infection Society and the Health Protection Agency
Correspondence to: Dr W S Lim, Respiratory Infection Research Group, Respiratory Medicine, Nottingham City Hospital, Nottingham NG5 1PB, UK; weashen@doctors.org.uk

References

Urinary leukotriene LTE4 levels in non-responders to antileukotriene therapy

I read with interest the recent article by Green et al showing that, in acute asthma, activation of leukotriene pathways correlated with the degree of airflow obstruction and a reduction in leukotriene levels was associated with resolution of asthma exacerbation. However, no analysis was performed on patients categorized as being in the treatment failure group which was reported to be as high as 10% of patients receiving intravenous montelukast.

The importance of this analysis cannot be understated as not everyone with asthma responds to antileukotriene therapy and non-responders have been reported to be as high as 50%.

It would have been interesting to observe urinary leukotriene LTE4 levels in the treatment failure group as it has been shown that cysteinyi leukotriene release from leucocytes of responders was higher than from non-responders which, in turn, correlated with the response to antileukotriene therapy.

D K C Lee
Ipswich Hospital, Ipswich IP4 5PD, UK; dkclee@doctors.org.uk

Authors’ reply
We thank Dr Lee for his interest in our reports. However, he appears to confuse the terms “treatment failure” and “non-responder”. “Treatment failure”, as defined in the original report for our study, referred to a clinical outcome (a composite end point of hospitalisation, need for excluded medication, or need for prolonged acute asthma treatment in the emergency setting). In contrast, “non-responder” generally refers to a subset of patients who fail to surpass a defined threshold of response. As we have commented previously using chronic asthma as an example, simplistic “responder/non-responder” analyses often fail to account for clinically important aspects of disease variability and the impact of a treatment intervention. Moreover, in our initial report of intravenous montelukast in acute asthma, a systematic analysis of baseline variables did not identify any factor which predicted response to intravenous montelukast in terms of either forced expiratory volume in 1 second (FEV1) or treatment failures, with the exception of baseline FEV1.

The present report addressed the relationship between FEV1 and cysteinyl leukotriene production as measured by LTE4 excretion. A similar analysis of treatment failures and LTE4 levels is complicated by the fact that, unlike baseline FEV1, which was measured before administration of the study drug, treatment failures tended to be reduced by intravenous montelukast.

Nevertheless, 27 of 201 patients (13.1%) in the montelukast group and 12 (18.2%) in the placebo group met one or more of the criteria for treatment failure during the study. Of these, 20 patients had LTE4 data for analyses. Compared with patients who did not meet the criteria for treatment failures and who had LTE4 data available (n = 161), LTE4 levels were numerically higher at baseline in the treatment failure group although this did not reach statistical significance (121.6 pg/ml creatinine (95% CI 91.5 to 161.6) vs 111.6 pg/ml creatinine (95% CI 100.0 to 128.5)). If Dr Lee’s hypothesis is correct, LTE4 levels should have been lower among the treatment failure. The data therefore suggest that, rather than serving as a useful predictor of clinical outcome, increased LTE4 levels are more likely to be a marker of worsened asthma severity, consistent with our analysis of LTE4 levels and FEV1. Taken together, the data provide a strong biological rationale for the observed benefit of antileukotriene therapy in acute asthma.

S A Green
Respiratory and Allergy, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ, USA; stuart.green@merck.com

References

Victory Project Congressi, Via G Modena 3a, 20129 Milan, Italy. Telephone: 02 89 05 35 24. Fax: 02 20 13 95. Email: info@victoryproject.it.

Rare Pulmonary Diseases and Orphan Drugs in Respiratory Medicine

A meeting on “Rare Pulmonary Diseases and Orphan Drugs in Respiratory Medicine” organized by the Department of Pneumology, Hospital San Giuseppe, Milan and the RZIP Study will take place on 25/26 February 2005 at the Congress Center Palazzo delle Stelline, Milan, Italy. For further information contact the Organizer Andrea Lentini, via G Modena 3a, 20129 Milan.

www.thoraxjnl.com

727

NOTICE

Rare Pulmonary Diseases and Orphan Drugs in Respiratory Medicine

A meeting on “Rare Pulmonary Diseases and Orphan Drugs in Respiratory Medicine” organized by the Department of Pneumology, Hospital San Giuseppe, Milan and the RZIP Study will take place on 25/26 February 2005 at the Congress Center Palazzo delle Stelline, Milan, Italy. For further information contact the Organizer Andrea Lentini, via G Modena 3a, 20129 Milan, Italy. Telephone: 02 89 05 35 24. Fax: 02 20 13 95. Email: info@victoryproject.it.